SOURCE: Anti Aging Medical Group Corp.

November 09, 2006 09:45 ET

Anti Aging Medical Group Corp. Establishes Collaboration With AlphaRx and Leading Neurologists for Alzheimer's Disease

TORONTO -- (MARKET WIRE) -- November 9, 2006 -- Anti Aging Medical Group Corp. (PINKSHEETS: AAGM) is very pleased to announce that the company, inline with its new corporate strategy to become a leading specialty pharmaceutical company in the multi billion anti aging pharmaceutical market, has entered into the neuro-protection prescription drug market through a collaboration with AlphaRx Inc. (OTCBB: ALRX) and a group of leading neurologists.

Without getting into specifics at this point, the collaboration will focus on the development of selective neuroprotective compounds for the prevention and treatment of age-related Dementia indications such as Alzheimer's.

The collaboration has selected a well-known compound which in various pre-clinical studies have demonstrated low toxicity and proven to be highly effective in reducing brain inflammation, protecting neuronal cells, restoring cognitive function and preventing the development of Alzheimer's. This has not been a priority by the major pharmaceutical companies due to various formulation issues.

In addition, the collaboration believes its approach of using nanotechnology to deliver such compound through the blood brain barrier is viable and will attempt to screen 2 to 3 formulations in Alzheimer's animal models to determine the right dosage for human trials.

About Anti Aging Medical Group Corp.

We are a specialty pharmaceutical company focused on developing, acquiring and commercializing innovative and scientifically proven products that offer both health maintenance and appearance enhancing benefits to all of us. For more information about us please visit our website at


This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the Company.

Contact Information